3-Dimensional Human iPSC-Derived Cardiac Organoids for Antifibrotic Drug Screening
Open Access
- 9 October 2026
- journal article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (9)
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic targetCell, 2024
- Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEFJACC, 2020
- Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac FibroblastsCirculation: Heart Failure, 2019
- Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomesBiomedicine & Pharmacotherapy, 2017
- Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart FailureJACC, 2007